Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (173)	10/24/2000 12:36:55 AM
From: sim1	Read Replies (1) \| Respond to of 724

Rick, If guesses are acceptable, my guess is 1998. '98 appears in one of the links in your post. www.training.nih.gov/jobfair/'98%20Participants/dgi.htm Further, the document in the link states... DGI presently has 19 employees* and discovery programs in anti-cancer, immunoregulators, neuroprotectives, and growth enhancers.* Whereas their web site currently states DGI BioTechnologies, Inc. is a biotechnology-based research company formed in January 1996 to develop its proprietary small molecule drug discovery platform, called Diogenesis®. DGI is majority owned, and fully funded by New Brunswick Scientific Co., Inc. (NBSC). DGI utilizes 10,000 sq. ft. of newly equipped laboratory space at NBSC's main facility in Edison, New Jersey. DGI presently has 30 employees in the fields of molecular immunology, molecular pharmacology, and structural biology. DGI will focus on the identification of novel site-directed assays and promising drug leads which regulate protein-protein interactions for license to pharmaceutical and biotechnology companies. Looks like their employee population has grown by 50% since that post. Currently advertised employment opportunities... Employment Positions DGI BioTechnologies, Inc. is a New Jersey company focused on the establishment of promising new drug assay platforms and discovering novel small molecule leads for license to pharmaceutical and biotechnology companies. Active research programs involve the design and construction of novel genes and proteins and obtaining structure-function data on drug targets and drug leads. We seek candidates for the following positions: Protein Technologies Group - Posting May 15, 2000 Scientists (Ph.D./MS/BS) We have an immediate opportunity for a Research Scientist to join our Protein Technologies group to study protein:protein interactions. The successful candidate will be expected to perform expression, purification, and analysis of recombinant proteins and synthetic peptides. The position also requires experience in Biacore molecular interaction analysis and/or development of in vitro phosphorylation assays. Experienced candidates at levels from BS through post-doc will be considered for this opportunity. The position requires strong verbal communication skills, as well as willingness to take initiative and contribute in a team environment. Send to attention of Michael Lennick. Molecular Biology Scientists (Ph.D./MS/BS) Individuals with demonstrated abilities in molecular biology desired. Expertise in phage display or protein expression technologies or experience in receptor-ligand interactions required. High-Throughput Screening Individuals responsible for developing and performing receptor binding assays and operation of automated equipment for high throughput screening. Experience with computers and relational databases a plus. Interested applicants are invited to send resume including salary requirements and references to: DGI Biotechnologies, Inc. P.O. Box 424 40 Talmadge Road Edison, NJ 08818-0424 Perhaps this might provide some hints. Stuart